GlassScriptPhysician profile
Naeem Akhtar
NPI 1831291863
$8,580.21
in general payments reported to CMS, 2019-2025
35 companies · $2,004 in 2025
The $2,004 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $394 · 2021: $789 · 2022: $1,688 · 2023: $1,688 · 2024: $1,364 · 2025: $2,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,039 · Education: $16.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,038.95 |
| Education | $16.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,425.55 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Celgene Corporation | $963.28 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $770.42 | 2019-2025 | Xifaxan, Relistor |
| Gilead Sciences, INC. | $701.57 | 2019-2025 | Vemlidy, Epclusa |
| Janssen Biotech, INC. | $448.77 | 2020-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $382.30 | 2024-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $311.16 | 2024-2025 | Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $269.98 | 2019-2024 | Entyvio |
| Pfizer INC. | $249.74 | 2019-2025 | |
| Madrigal Pharmaceuticals | $190.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $186.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.11 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $153.92 | 2020-2024 | |
| Novo Nordisk INC | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.36 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $110.17 | 2023 | Farxiga |
| Regeneron Pharmaceuticals, INC. | $107.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $100.00 | 2019 | |
| Boston Scientific Corporation | $97.52 | 2019-2023 | Exalt Model D |
| Cook Medical LLC | $96.83 | 2025 | Echotip Insight |
| Nestle Healthcare Nutrition INC. | $79.23 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $68.67 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $59.46 | 2019-2025 | |
| Qol Medical, LLC | $54.98 | 2023-2024 | Sucraid, Sucraid |
| Vivus LLC | $54.34 | 2019-2023 | Pancreaze |
| Ardelyx, INC. | $53.01 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $50.34 | 2024-2025 | Omvoh |
| Olympus America INC. | $38.86 | 2023 | Evis Exera III Xenon Light Source |
| Mirum Pharmaceuticals, INC. | $29.21 | 2024 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.60 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $19.72 | 2024 | Dificid |
| Alfasigma USA, INC. | $18.62 | 2020 | |
| Celltrion USA INC. | $16.84 | 2023 | Yuflyma |
| Shionogi INC | $14.68 | 2020 | |
| Allergan, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naeem Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.